We demonstrate that overexpression of the lysosomal enzyme, ASAH, not only reduces hepatic ceramides, as anticipated, but also normalizes hepatic and adipose tissue insulin sensitivity and improves hepatic steatosis despite ongoing alcohol consumption, a clinical scenario faced by the majority of patients who have ALD. The gene discussed is INS; the disease is Hepatic steatosis.